Global Cell Therapy Technologies Market Report 2022: Development of Cutting-Edge Techniques Driving Sector Forward – Yahoo Finance
Cell Therapy Technologies Market
Dublin, Dec. 08, 2022 (GLOBE NEWSWIRE) — The “Cell Therapy Technologies Market Share, Size, Trends, Industry Analysis Report, By Product; By Process; By Cell Type; By End-Use; By Region; Segment Forecast, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The global cell therapy technologies market size is expected to reach USD 12.27 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
The development of cutting-edge cellular therapy technologies has been made possible by the emergence of new technologies. Companies are using new technologies to boost their product development plans by entering into out-licensing or co-development agreements with other parties in addition to expanding their product line.
Researchers are investing a lot of money in the creation of such efficient and secure treatments as an alternative to traditional treatment modalities, which is another factor contributing to the industry expansion. Oncology has the most active clinical trials out of all therapeutic specialties. For clinical research, T cells, CD34+ and/or CD133+ stem cells, and mesenchymal stem/stromal cells are primarily used.
Additionally, a component that was negatively impacted in 2020, further impacting industry growth, is the requirement for successful commercial translation of cell-based therapy technologies. This factor requires large and stable funding.
Cell therapy Technologies Market Report Highlights
Cell therapy equipment segment is anticipated to grow at an escalating over the forecast period owing to act of replacing, mending, restoring, or regenerating damaged tissues, cells, and organs, cell-based therapies have significant potential.
Cell processing accounted for largest of the global revenue share which is due to increased Viral vectors are now the primary delivery modality among end users, as seen by the exponential rise in the number of viral vector-based R&D initiatives.
Stem cells sector is expected to grow during the forecast period. This growth is attributed to increased research and development initiatives taken.
Research institutes and cell banks sector accounted for the largest revenue share over the forecast period due to the widespread of lymphatic and neuro stimulated disorders and researches in accordance to develop a cure for it.
North America is expected to grow at a significant CAGR over the projected period on account of fast acting insulin demand in the region is being driven by rising diabetes rates and an aging population.
Report Attribute
Details
No. of Pages
118
Forecast Period
2022 – 2030
Estimated Market Value (USD) in 2022
$4.14 billion
Forecasted Market Value (USD) by 2030
$12.27 billion
Compound Annual Growth Rate
14.5%
Regions Covered
Global
The publisher has segmented the cell therapy technologies market report based on product, process, cell type, end-use, and region:
Long-acting insulin, Product Outlook (Revenue – USD Billion, 2022 – 2030)
Media, Sera, and Reagents
Cell Engineering Products
Cell Culture Vessels
Cell Therapy Equipment
Cell Processing Equipment
Single-use Equipment
Other Equipment
Systems and Software
Other Products
Long-acting insulin, Process Outlook (Revenue – USD Billion, 2022 – 2030)
Cell Processing
Cell Preservation
Distribution and Handling
Process Monitoring and Quality Control
Long-acting insulin, Cell Type Outlook (Revenue – USD Billion, 2022 – 2030)
T-Cells
Stem Cells
Other Cells
Long-acting insulin, End-Use Channel Outlook (Revenue – USD Billion, 2022 – 2030)
Biopharmaceutical and Biotechnology Companies
CROs and CMOs
Research Institutes and Cell Banks
Long-acting insulin, Regional Outlook (Revenue – USD Billion, 2022 – 2030)
North America
U.S
Canada
Europe
Germany
UK
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Research Methodology
4. Global Cell Therapy Technologies Market Insights
5. Global Cell Therapy Technologies Market, by Product
6. Global Cell Therapy Technologies Market, by Process
7. Global Cell Therapy Technologies Market, by Cell Type
8. Global Cell Therapy Technologies Market, by End-Use
9. Global Cell Therapy Technologies Market, by Geography
10. Competitive Landscape
11. Company Profiles
Companies Mentioned
Thermo Fisher Scientific Inc.
Merck KGaA
Danaher Corporation
Becton Dickinson and Company
Lonza Group
Sartorius AG
Terumo BCT.
For more information about this report visit https://www.researchandmarkets.com/r/idd2uq
Attachment
Cell Therapy Technologies Market
Is it time to bet on a turnaround?
At age 51, Anne Schieber was broke and disillusioned. She had worked for the IRS for 23 years and was regarded as one of the agency’s top auditors. But she never got promoted and never earned more than $3,150 in a year. With half her life already behind her, her retirement prospects looked bleak. But Schieber had learned a powerful secret from years of studying the tax returns of America’s richest residents. Over the next 50 years, it earned her a 449,000% return — making Schieber one of the mos
Wake up and smell the diesel.
Investors searching for that feeling telling you market sentiment is shifting to a more positive outlook have been brought down to earth again. Following 2022’s market behavior to a tee, the recent rally has run into a brick wall. To wit, the S&P 500 notched 5 consecutive negative sessions over the last week with investors mulling over the prospect of a recession. Indeed, financial experts have been sounding the warning bells on the precarious state of the global economy. One of the doomsayers h
Yahoo Finance Live's Seana Smith breaks down the stocks trending in the after-hours trading session.
In this article, we will discuss the 14 Best Marijuana Stocks To Buy Now. You can skip our detailed industry analysis and go directly to the 5 Best Marijuana Stocks To Buy Now. The cannabis industry is expected to undergo rapid changes in the coming years. One reason is the increasing awareness of the health benefits […]
Granted, some of the highest-quality stocks have lofty share prices. You can invest in one of the best renewable energy companies around in one of two ways — buy shares of Brookfield Renewable Partners (NYSE: BEP) or buy shares of Brookfield Renewable Corporation (NYSE: BEPC). One big plus for Brookfield Renewable Partners is its distribution.
What to watch in markets on Friday, December 9, 2022.
Buy and hold forever? Not always.
If you've been trading on TD Ameritrade, get ready to say goodbye. TD Ameritrade clients are being notified now their accounts are being moved into Charles Schwab starting next year. It's a long-awaited move after Schwab bought TD Ameritrade in 2019.
ARK ETF Founder Cathie Wood joins Yahoo Finance Live for a wide-ranging interview on the state of the crypto market, Elon Musk, Fed policy, Teladoc, and more.
For long-term investors with capital to deploy in the current market, it's still a great time to put money to work in wonderful stocks with robust underlying businesses. While stocks across most sectors have declined over the past year, it's vital that investors not confuse share price fluctuations with the potential of an underlying business. As always, a look beyond the share price of a company and a close evaluation of the underlying business are keys before you buy or sell a stock.
A looming recession isn't stopping the world's most successful investors from buying their favorite stocks.
Crescent Point Energy Corp. ("Crescent Point" or the "Company") (TSX: CPG) (NYSE: CPG) is pleased to announce it has entered into an agreement to acquire additional Kaybob Duvernay assets and is increasing its base dividend.
Yahoo Finance's Jared Blikre highlights which stocks are making moves at the end of the trading session on Thursday.
Carnival (NYSE: CCL) (NYSE: CUK) had a difficult time during the early days of the pandemic. Carnival faces the impact of higher interest rates on its variable-rate borrowings, which could lead to higher costs. Demand for cruising is back, and Carnival is progressing toward its earnings goals.
Smartphones have become a necessity, and that's good news for telecom giants AT&T and Verizon. If you're a risk-averse dividend investor who wants to cut your exposure to the state of the economy, the telecom giants may not be the best choice. A better choice is American Tower (NYSE: AMT), which just hiked its quarterly dividend by 6.1%.
The outlook remains dim for Carvana.
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors are buying Nio stock before 2022 ends as they believe the worst is over for the electric vehicle maker.